NCT05875610View on ClinicalTrials.gov

Preventive Approach Using Venlafaxine

PHASE4UnknownINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 1, 2023

Primary Completion Date

October 1, 2023

Study Completion Date

December 1, 2023

Conditions
Peripheral Neuropathy Due to Chemotherapy
Interventions
DRUG

Venlafaxine 75 MG

Venlafaxine 75 mg extended release capsules for a 7-days duration

DRUG

Gabapentin 400 mg

Gabapentin 400 mg capsules

Trial Locations (1)

Unknown

RECRUITING

Mit Ghamr Oncology Center, Al Mansurah

Sponsors
All Listed Sponsors
lead

Mit Ghamr Oncology Center

OTHER